Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844649 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 861
- Enrollment target
NCT00844649: Completed Phase 3 study, sponsored by Celgene.
NCT00844649 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 861 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00844649, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 861 participants
- Enrollment target
Study Summary
Phase III Metastatic Pancreatic Cancer
Primary Outcome
Overall survival was defined as the time from the date of randomization to the date of death from all causes. Participants who did not die were censored at the last known time the participant was alive. Patient survival was summarized using Kaplan-Meier methods.
Interventions
- DRUG Gemcitabine
- DRUG Albumin-bound paclitaxel (ABI-007)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2009-03-01 |
| Est. Completion | 2013-04-09 |
| Phase | Phase 3 |
What the finished NCT00844649 record still lists
NCT00844649 is an interventional study that assigns participants to a tested intervention. The registered 861 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00844649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00844649 about?
NCT00844649 is a clinical study titled "Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas". Phase III Metastatic Pancreatic Cancer
What is the current status of trial NCT00844649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 861 participants. The study started on 2009-03-01. Estimated completion is 2013-04-09.
What interventions are being tested in trial NCT00844649?
The interventions under investigation include: Gemcitabine (DRUG), Albumin-bound paclitaxel (ABI-007) (DRUG).
Who is sponsoring clinical trial NCT00844649?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00844649's enrollment target sits among peer trials
861 380th of 2000 higher than 1,621 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI